Business context and reporting period
GT Biopharma, Inc. filed this Form 10-K for the fiscal year ended December 31, 2022. The company is a clinical-stage biopharmaceutical developer focused on its TriKE natural-killer-cell engager platform. It has no approved products and has not generated product revenue.
Its lead program GTB-3550 completed Phase 1 enrollment in 2021; the company is replacing it with next-generation GTB-3650 for AML/MDS. GTB-5550 is a preclinical B7-H3-targeted candidate for solid tumors.
Financial performance and position
| Metric | FY2022 / December 31, 2022 | Prior comparable period |
|---|---|---|
| Revenue | $0 | $0 in 2021 |
| Research and development expense | $8.8 million | $9.6 million in 2021 |
| Selling, general and administrative expense | $12.4 million | $47.9 million in 2021 |
| Total operating expenses | $21.3 million | $57.5 million in 2021 |
| Net loss | $20.9 million; $0.66 per share | $58.0 million; $2.06 per share |
| Net cash used in operating activities | $15.2 million | $15.6 million in 2021 |
| Cash and cash equivalents | $5.7 million | $9.0 million |
| Short-term investments | $10.8 million | $23.0 million |
| Total assets / total liabilities | $16.7 million / $5.0 million | $32.2 million / $10.3 million |
Gross and operating margins are not meaningful because the company reported no revenue. Interest income was $292,000, versus $38,000 in 2021; interest expense fell to $8,000 from $718,000. No convertible notes were outstanding at year-end. Accounts payable included $2.3 million owed to the contract manufacturer. The company reported an accumulated deficit of $674.5 million.
Changes versus 2021
- Net loss narrowed by $37.1 million, principally as SG&A fell by $35.5 million. Management attributed the reduction largely to lower payroll and stock-compensation expense, marketing and investor-relations costs, and legal and professional fees.
- R&D expense decreased $780,000, mainly due to reduced stock compensation. Management expected direct clinical and preclinical costs to rise significantly in 2023.
- Cash plus short-term investments declined $15.5 million year over year. Operating cash use remained broadly similar, while 2021 financing had included a $24.7 million stock offering and $16.4 million from warrant exercises.
- 2022 included $7.7 million of noncash stock compensation, including $3.0 million for vested options. The company also issued 1.22 million shares, valued at $3.2 million, as part of settling manufacturer obligations.
Outlook, risks and unusual items
- Liquidity: On January 4, 2023, the company raised $6.5 million gross through an offering of shares and warrants. Management estimated approximately $15.0 million in cash needs for the next 12 months and said the approximately $23.0 million of cash and short-term investments available after the offering would fund operations for at least 12 months from issuance of the financial statements. It expects to seek further funding as it enters Phase 1 trials. The financial statements are prepared on a going-concern basis; management cautioned that additional financing is needed and is not assured.
- Development plans: The company anticipated filing an IND for GTB-3650 in the first half of 2023 and starting a relapsed/refractory AML and high-grade MDS study by year-end 2023. For GTB-5550, it anticipated an IND filing in late 2023 and a study in the first half of 2024. These are forward-looking targets, not guaranteed outcomes.
- Clinical evidence: In the completed GTB-3550 Phase 1 trial, 12 patients received escalating doses. The company reported the therapy was generally well tolerated, with no serious cytokine-release-syndrome cases; four patients had transient reductions in bone-marrow leukemic blasts. These early results do not establish efficacy.
- Execution and funding risks: The company relies on third parties for clinical work and manufacturing, has no manufacturing facilities or alternate supply, and reported only two full-time employees plus eight consultants. It has no commercial sales force. Clinical success, regulatory approval, commercialization and profitability remain uncertain.
- Listing and dilution: Nasdaq notified the company in February 2023 that its bid price had been below $1 for 30 consecutive business days, giving it until August 21, 2023 to regain compliance. The January 2023 financing included common and pre-funded warrants and warrants to purchase additional shares; equity financing may dilute existing holders.
- Legal matters: A March 2023 demand letter from an alleged convertible-note holder claimed shares due on conversion in 2022 were not delivered and sought liquidated damages; the company denied liability. The company also pursued arbitration against its former CFO, seeking damages and other relief; the hearing was scheduled to begin May 15, 2023. A separate former-CEO dispute was settled in 2022, including return and cancellation of 1.845 million shares.
- Controls and audit: Management said previously reported material weaknesses in internal controls were remediated by December 31, 2022 and disclosure controls were effective. The auditor issued an unqualified opinion on the financial statements and identified liquidity assessment as a critical audit matter; it did not provide an opinion on internal-control effectiveness.
- Other key risks include clinical-trial delays or failures, regulatory and safety setbacks, dependence on University of Minnesota license rights, manufacturing costs and supply, competition, stock-price volatility, and continuing cash needs. COVID-19 affected operations, but the company reported no related asset impairment or significant fair-value change.
Most important facts for investors to verify
- Whether available cash, short-term investments and any subsequent financing adequately fund the clinical plan, and the timing and terms of additional capital needs.
- Whether GTB-3650 and GTB-5550 meet the stated IND and trial milestones, including manufacturing readiness and drug-supply availability.
- The full clinical-trial data for GTB-3550 and the design, endpoints, enrollment and safety monitoring planned for successor trials.
- The outcome of the Nasdaq bid-price deficiency and any resulting listing or financing consequences.
- The resolution and potential financial impact of the noteholder demand and former-CFO arbitration, as well as any continuing obligations to the contract manufacturer.
- Share dilution from outstanding and newly issued warrants, stock compensation, and any further equity offerings.